October 31st, 2013
Does OPTIMIZE Reveal the Optimal DAPT Time Frame?
In the OPTIMIZE trial of 3119 patients with stable coronary artery disease or low-risk ACS treated with zotarolimus-eluting stents, 3 months of dual antiplatelet therapy (DAPT) was noninferior to 12 months for net adverse clinical and cerebral events (composite of all-cause death, MI, stroke, or major bleeding) without significantly increasing the risk of stent thrombosis. Tell us:
- In what percentage of your PCI cases do you use a zotarolimus stent?
- Are the results unique to the zotarolimus-eluting DES or applicable to other second generation (i.e., everolimus-eluting) DES?
- Does this study persuade you to administer DAPT for 3 months rather than 12 months to low-risk patients treated with a DES?
To read more about OPTIMIZE, click here for our news story.